Document is current
Any future updates will be listed below
-
Authors
Silverstein, Rachel A.
Kim, Nahye
Kroell, Ann-Sophie https://orcid.org/0000-0001-9986-0737
Walton, Russell T. https://orcid.org/0000-0002-0546-474X
Delano, Justin https://orcid.org/0000-0002-7988-5352
Butcher, Rossano M.
Pacesa, Martin https://orcid.org/0000-0003-1560-5769
Smith, Blaire K.
Christie, Kathleen A.
Ha, Leillani L. https://orcid.org/0000-0003-4478-660X
Meis, Ronald J.
Clark, Aaron B.
Spinner, Aviv D.
Lazzarotto, Cicera R.
Li, Yichao https://orcid.org/0000-0001-5791-096X
Matsubara, Azusa https://orcid.org/0009-0007-1637-6386
Urbina, Elizabeth O.
Dahl, Gary A.
Correia, Bruno E. https://orcid.org/0000-0002-7377-8636
Marks, Debora S.
Tsai, Shengdar Q. https://orcid.org/0000-0001-9161-3993
Pinello, Luca https://orcid.org/0000-0003-1109-3823
De Ravin, Suk See https://orcid.org/0000-0002-9800-774X
Liu, Qin
Kleinstiver, Benjamin P. https://orcid.org/0000-0002-5469-0655
- License Information
-
More Information
Article History
Received: 11 April 2024
Accepted: 14 April 2025
First Online: 22 April 2025
Competing interests
: R.A.S. and B.P.K. are inventors on a patent application filed by Mass General Brigham (MGB) that describes the development of PAMmla. B.P.K. and R.T.W. are inventors on additional patents or patent applications filed by MGB that describe genome engineering technologies related to the current study. S.Q.T. is an inventor on a patent application for GUIDE-seq, and is a member of the scientific advisory boards of Ensoma and Prime Medicine. L.P. has financial interests in Edilytics and SeQure Dx. Q.L. is a consultant for Entrada Therapeutics. B.P.K. is a consultant for EcoR1 capital, Novartis Venture Fund and Jumble Therapeutics, and is on the scientific advisory boards of Acrigen Biosciences, Life Edit Therapeutics and Prime Medicine. B.P.K. has a financial interest in Prime Medicine, Inc., a company developing therapeutic CRISPR–Cas technologies for gene editing. The interests of L.P. and B.P.K. were reviewed and are managed by MGH and MGB in accordance with their conflict-of-interest policies. The other authors declare no competing interests.
